Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa Bodei

Showing results (111-120 of 184) with videos related to

Pageof 19
Sort By:
Cancer Treatment Reviews|December 7, 2010
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomasNicola Fazio, Saverio Cinieri, Katia Lorizzo, et al.
Journal of the Endocrine Society|September 1, 2021
Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary CarcinomaAndrew L Lin, Viviane Tabar, Robert J Young, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 8, 2004
Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomasLisa Bodei, Daria Handkiewicz-Junak, Chiara Grana, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 8, 2020
Comparison of <sup>68</sup>Ga-DOTA-JR11 PET/CT with dosimetric <sup>177</sup>Lu-satoreotide tetraxetan (<sup>177</sup>Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapySimone Krebs, Joseph A O'Donoghue, Evan Biegel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 16, 2011
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compoundsFrancesco Giammarile, Lisa Bodei, Carlo Chiesa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 31, 2023
Lesion Dosimetry for [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate CancerMilan Grkovski, Joseph A O'Donoghue, Brandon S Imber, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 23, 2015
Long-term results of PRRT in advanced bronchopulmonary carcinoidAnnapaola Mariniello, Lisa Bodei, Carmine Tinelli, et al.
Cancer|July 16, 2024
Update in the management of gastroenteropancreatic neuroendocrine tumorsAndrew J H Sedlack, Diana Grace Varghese, Amirkia Naimian, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2006
Dopamine receptor expression and function in corticotroph ectopic tumorsRosario Pivonello, Diego Ferone, Wouter W de Herder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 23, 2018
Correlation of dose with toxicity and tumour response to <sup>90</sup>Y- and <sup>177</sup>Lu-PRRT provides the basis for optimization through individualized treatment planningMarta Cremonesi, Mahila Esmeralda Ferrari, Lisa Bodei, et al.
Pageof 19

Showing results (111-120 of 184) with videos related to

Sort By:
Pageof 19
Cancer Treatment Reviews|December 7, 2010
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomasNicola Fazio, Saverio Cinieri, Katia Lorizzo, et al.
Journal of the Endocrine Society|September 1, 2021
Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary CarcinomaAndrew L Lin, Viviane Tabar, Robert J Young, et al.
Cancer Biotherapy & Radiopharmaceuticals|April 8, 2004
Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomasLisa Bodei, Daria Handkiewicz-Junak, Chiara Grana, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 8, 2020
Comparison of <sup>68</sup>Ga-DOTA-JR11 PET/CT with dosimetric <sup>177</sup>Lu-satoreotide tetraxetan (<sup>177</sup>Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapySimone Krebs, Joseph A O'Donoghue, Evan Biegel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 16, 2011
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compoundsFrancesco Giammarile, Lisa Bodei, Carlo Chiesa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 31, 2023
Lesion Dosimetry for [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy Combined with Stereotactic Body Radiotherapy in Patients with Oligometastatic Castration-Sensitive Prostate CancerMilan Grkovski, Joseph A O'Donoghue, Brandon S Imber, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 23, 2015
Long-term results of PRRT in advanced bronchopulmonary carcinoidAnnapaola Mariniello, Lisa Bodei, Carmine Tinelli, et al.
Cancer|July 16, 2024
Update in the management of gastroenteropancreatic neuroendocrine tumorsAndrew J H Sedlack, Diana Grace Varghese, Amirkia Naimian, et al.
The Journal of Clinical Endocrinology and Metabolism|October 13, 2006
Dopamine receptor expression and function in corticotroph ectopic tumorsRosario Pivonello, Diego Ferone, Wouter W de Herder, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 23, 2018
Correlation of dose with toxicity and tumour response to <sup>90</sup>Y- and <sup>177</sup>Lu-PRRT provides the basis for optimization through individualized treatment planningMarta Cremonesi, Mahila Esmeralda Ferrari, Lisa Bodei, et al.
Pageof 19